Almost thirty percent of the protein targets currently under exploration and study constitute
the protein kinases which have always attracted the pharmaceutical companies as they are easy targets
for drug development. Although the kinases will remain major focus of oncology for many years to
come in the development of anticancer drugs, the number of kinase inhibitors as therapeutic targets
for the treatment of several other diseases which are undergoing clinical trials are exponentially increasing.
In this review, we discuss very briefly the different types of protein kinases that have been
used as targets for developing drugs for cancer, inflammation, autoimmune disease, heart disease and